These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
190 related items for PubMed ID: 26858026
1. Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA. Laribi K, Bolle D, Ghnaya H, Sandu A, Besançon A, Denizon N, Truong C, Pineau-Vincent F, de Materre AB. Ann Hematol; 2016 Apr; 95(5):765-9. PubMed ID: 26858026 [Abstract] [Full Text] [Related]
4. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. D'Arena G, Califano C, Annunziata M, Tartarone A, Capalbo S, Villani O, Amendola G, Pietrantuono G, Ferrara F, Pinto A, Musto P, D'Arco AM, Cascavilla N. Eur J Haematol; 2007 Jul; 79(1):53-8. PubMed ID: 17532766 [Abstract] [Full Text] [Related]
5. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. Maung SW, Leahy M, O'Leary HM, Khan I, Cahill MR, Gilligan O, Murphy P, McPherson S, Jackson F, Ryan M, Hennessy B, McHugh J, Goodyer M, Bacon L, O'Gorman P, Nee A, O'Dwyer M, Enright H, Saunders J, O'Keeffe D. Br J Haematol; 2013 Oct; 163(1):118-22. PubMed ID: 23909468 [Abstract] [Full Text] [Related]
6. A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia. Piatek CI, Bocian H, Algaze S, Weitz IC, O'Connell C, Liebman HA. Acta Haematol; 2020 Oct; 143(3):244-249. PubMed ID: 31665725 [Abstract] [Full Text] [Related]
8. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet AS, Vital-Durand D, Lega JC. Autoimmun Rev; 2015 Apr; 14(4):304-13. PubMed ID: 25497766 [Abstract] [Full Text] [Related]
13. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, Lunghi M, Tassinari C, Alfinito F, Ferrari A, Leporace AP, Niscola P, Carpenedo M, Boschetti C, Revelli N, Villa MA, Consonni D, Scaramucci L, De Fabritiis P, Tagariello G, Gaidano G, Rodeghiero F, Cortelezzi A, Zanella A. Blood; 2014 Nov 06; 124(19):2930-6. PubMed ID: 25232059 [Abstract] [Full Text] [Related]
16. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Pamuk GE, Pamuk ON, Başlar Z, Ongören S, Soysal T, Ferhanoğlu B, Aydin Y, Ulkü B, Aktuğlu G, Akman N. Ann Hematol; 2002 Aug 06; 81(8):436-40. PubMed ID: 12224000 [Abstract] [Full Text] [Related]
18. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R. Haematologica; 2002 Feb 06; 87(2):189-95. PubMed ID: 11836170 [Abstract] [Full Text] [Related]
19. Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants. Svahn J, Fioredda F, Calvillo M, Molinari AC, Micalizzi C, Banov L, Schmidt M, Caprino D, Marinelli D, Gallisai D, Dufour C. Br J Haematol; 2009 Apr 06; 145(1):96-100. PubMed ID: 19208098 [Abstract] [Full Text] [Related]